Fluticasone Propionate is a potent, synthetic, topical corticosteroid of the glucocorticoid class. In the 0.05% w/w concentration, it is primarily formulated for dermatological use. It exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by binding to the glucocorticoid receptor, leading to the inhibition of multiple inflammatory cytokines. It is considered a high-potency topical corticosteroid according to the Indian classification system.
Adult: Apply a thin film to the affected area once or twice daily, as directed by the physician. For most conditions, once-daily application is sufficient. Treatment should not exceed 4 weeks continuously.
Note: 1. Wash and dry hands and affected area before application. 2. Apply a thin layer and rub gently until it disappears. 3. Do not bandage, cover, or wrap the treated area unless directed. 4. Avoid contact with eyes, mouth, nose, and mucous membranes. 5. Wash hands after application unless hands are the treatment area.
Fluticasone propionate is a potent glucocorticoid receptor agonist. It diffuses across cell membranes and binds with high affinity to cytoplasmic glucocorticoid receptors. The receptor-ligand complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA. This modulates gene transcription, leading to the synthesis of anti-inflammatory proteins (like lipocortin) and the inhibition of synthesis of pro-inflammatory mediators.
Pregnancy: Pregnancy Category C (US FDA). Animal studies show teratogenicity. No adequate, well-controlled studies in pregnant women. Should be used only if the potential benefit justifies the potential risk to the fetus. Use the minimum effective dose for the shortest duration. Avoid large areas or long-term use.
Driving: No known effects on driving ability.
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin) | May inhibit the metabolism of systemically absorbed fluticasone, increasing the risk of systemic corticosteroid side effects and HPA axis suppression. | Major |
| Other Topical Corticosteroids | Concomitant use increases the cumulative steroid exposure, raising the risk of local and systemic adverse effects. | Major |
| Live Vaccines | Systemic immunosuppression may impair antibody response and increase risk of vaccine-induced infection. Avoid vaccination during treatment. | Moderate |
Same composition (Fluticasone Propionate (0.05% w/w)), different brands: